ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.

Start Date01 Dec 2024

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

ACTRN12624000812594

/ Not yet recruitingNot ApplicableIIT

Assessing the effects of a broccoli sprout extract on endothelial function in healthy non-pregnant and pregnant women, and pregnant women with a hypertensive disorder of pregnancy

Start Date01 Nov 2024

Sponsor / Collaborator

Monash Health

ACTRN12624000972527

/ Not yet recruitingNot ApplicableIIT

Targeting ferroptosis in diabetes and diabetic complications by hydrogen (per)sulfide in males 18 - 65 years old

Start Date15 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Sulforadex

100 Translational Medicine associated with Sulforadex

100 Patents (Medical) associated with Sulforadex

4,253

Literatures (Medical) associated with Sulforadex

01 Dec 2025·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1

Article

Author: Zhang, Chang ; Cao, Deliang ; Hu, Wei ; Xia, Jiliang ; Li, Junjun ; Zhao, Hongyan ; He, Fen ; Sun, Jingqi ; Luo, Cong ; Zeng, Xi ; Lu, Zhongwei ; Sun, Weichu

PURPOSE:

Osteolysis is a common complication in patients with multiple myeloma (MM). Our previous studies have demonstrated that MM cells can promote osteoclast differentiation of macrophages. In this study, we explored the effect of sulforaphane (SFN), a natural NRF2 activator found in broccoli, on MM cell-induced osteoclast differentiation.

METHODS:

Conditional medium (CM) derived from MM cells was used to induce osteoclast differentiation, and TRAP staining was performed to examine osteoclast. Gene expression was detected by western blotting or real-time PCR. Cell counting and EdU staining were performed to test macrophage proliferation.

RESULTS:

We showed that the CM of MM cells downregulated the expression of ferroportin1 (Fpn1), the only known iron exporter in vertebrate cells, thereby increasing cellular iron levels in murine macrophage cells RAW264.7. Deferoxamine (DFO), an iron chelator, effectively blocked MM cell CM-induced osteoclast differentiation and macrophage proliferation, suggesting that iron overload played a key role in these cellular events. Subsequent mechanistic investigations revealed that MM cell CM induced osteoclast differentiation and macrophage proliferation by activating the JNK/AP-1/NFATC1 pathway and PI3K/AKT pathway. SFN was found to increase Fpn1 expression, leading to decreased cellular iron levels in RAW264.7 cells activated by MM cell CM. Importantly, the osteoclast differentiation and macrophage proliferation induced by MM cell CM were significantly inhibited by SFN.

CONCLUSION:

Altogether, our findings indicated that SFN inhibits MM cell-induced osteoclast differentiation and macrophage proliferation by elevating FPN1 levels. SFN could be a promising therapeutic strategy for MM-associated osteolysis.

03 Mar 2025·Artificial cells, nanomedicine, and biotechnologyQ2 · ENGINEERING & TECHNOLOGY

Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro , ex vivo and in vivo assessments

Q2 · ENGINEERING & TECHNOLOGY

ArticleOA

Author: Soni, Kriti ; Kohli, Kanchan ; Rizwanullah, Md.

In the present study, sulforaphane (SFN)-loaded nanostructured lipid carriers (NLC) were developed and optimized for improved oral efficacy against cancer. The SFN-loaded NLC formulation was developed by melt emulsification ultrasonication technique and optimized by Box-Behnken statistical design. The optimized SFN-loaded NLC formulation composed of precirol^® ATO 5 (solid lipid) and vitamin E (liquid lipid) as lipid phase (3% w/v), poloxamer 188 (1%) and Tween 80 (1%) as surfactant. The mean particle size, polydispersity index, zeta potential, entrapment efficiency (%) and drug loading (%) of optimized SFN-loaded NLC formulation was observed to be 145.38 ± 4.46 nm, 0.181 ± 0.023, -25.12 ± 2.36 mV, 84.94 ± 3.82% and 14.82 ± 3.46%, respectively. In vitro drug release studies showed that the release of SFN from optimized NLC formulation was significantly higher (86.52 ± 5.48%) compared to SFN suspension (38.47 ± 5.52%) up to 24 h. Ex vivo gut permeation studies revealed a very good enhancement in permeation of drug present in the NLC compared to plain SFN solution and were further confirmed by CLSM. MTT assay in different cancer cell lines showed that the optimized SFN-loaded NLC formulation exhibited significantly improved (p < .05) cytotoxicity compared to free SFN solution. SFN-loaded NLC formulation showed significantly improved antioxidant activity compared to free SFN solution. Furthermore, pharmacokinetic study on albino Wistar rats showed 5.04-fold increase in relative oral bioavailability with NLC (p < .05) compared to SFN suspension. Therefore, NLC represents a great potential for improved efficacy of SFN after oral administration.

01 Mar 2025·Metabolism open

Supplementation with aspalathin and sulforaphane protects cultured cardiac cells against dyslipidemia-associated oxidative damage

Article

Author: Orlando, Patrick ; Dludla, Phiwayinkosi V ; Muller, Christo J F ; Nkambule, Bongani B ; Tiano, Luca ; Mazibuko-Mbeje, Sithandiwe E ; Silvestri, Sonia ; Mthembu, Sinenhlanhla X H

Dyslipidemia is a prominent pathological feature responsible for oxidative stress-induced cardiac damage. Due to their high antioxidant content, dietary compounds, such as aspalathin and sulforaphane, are increasingly explored for their cardioprotective effects against lipid-induced toxicity. Cultured H9c2 cardiomyoblasts, an in vitro model routinely used to assess the pharmacological effect of drugs, were pretreated with the dietary compounds, aspalathin (1 μM) and sulforaphane (10 μM) before exposure to palmitic acid (0.25 mM) to induce lipidemic-related complications. The results showed that both aspalathin and sulforaphane enhanced cellular metabolic activity and improved mitochondrial respiration correlating with improved mRNA expression of genes involved in mitochondrial function, including uncoupling protein 2, peroxisome proliferator-activated receptor, gamma coactivator 1-alpha, nuclear respiratory factor 1, and ubiquinol-cytochrome c reductase complex assembly factor 1. Beyond attenuating lipid peroxidation, the dietary compounds also suppressed intracellular reactive oxygen species and enhanced antioxidant responses, including the mRNA expression of nuclear factor erythroid 2-related factor 2. These envisaged benefits were associated with decreased cellular apoptosis. This preclinical study supports and warrants further investigation into the potential benefits of these dietary compounds or foods rich in aspalathin or sulforaphane in protecting against lipid-induced oxidative damage within the myocardium.

News (Medical) associated with Sulforadex

04 Mar 2024

·www.biospace.com

Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients

Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the ability of QuadraMune® and similar compositions, to stimulate natural killer (NK) cell activity in patients with COVID-19. NK cells are the first line of defense against viruses and cancers1. The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents: Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2. It is published that this enzyme plays a fundamental role in immune suppression by cancer3, as well as numerous viruses including SARS-CoV-2, the causative agent of COVID-194. Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5. Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6. Patent #11759495, covering upregulation of T regulatory cells for suppression of suicidal ideation7. “In addition to this important validation from the USPTO, the fact that the ingredients in QuadraMune® have been reported by institutions such as Johns Hopkins University to suppress SARS-CoV-2 is strongly encouraging,” said Famela Ramos, Vice President of Business Development for the Company. “Our Company is driven by a desire to address unmet medical needs, whether it is through developing state of the art stem cell and gene therapies, or science-backed nutraceuticals,” said Timothy Dixon, President, and CEO of the Company. “The importance of NK cells in protecting the body against cancer and viruses is well known, the fact that this can be performed using a low-cost nutraceutical approach has implications in both oncology and virology.” About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is . 1 Cerwenka and Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001 Oct;1(1):41-9. 2 3 Ricuitti et al. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2019 Apr:196:105-116. 4 Guo et al. Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19. J Pathol. 2022 Mar;256(3):256-261. 5 6 7 8 Johns Hopkins University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies | BioSpace

Immunotherapy

17 Jan 2024

·www.pharmaceutical-technology.com

Stalica raises $17.5m to advance neurology programmes

The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. Image Credit: Alex and Maria photo / Shutterstock. Switzerland-based Stalica has raised $17.5m in Series B financing to fund clinical trials for its neuropsychiatric and neurological disorders pipeline. The clinical programmes that the company plans to use the Series B proceeds include the fixed-dose combination drug STP1 and mavoglurant (STP7). Furthermore, the company will also strengthen the data package for STP2. Stalica’s clinical pipeline STP1 is a fixed dose combination of ibudilast, a phosphodiesterase (PDE) 4/3 inhibitor, and bumetanide, a sodium (Na)- potassium (K)- chloride (Cl) cotransporter (NKCC) 1 agonist. Stalica is developing the precision therapy as a treatment for autism spectrum disorder (ASD) in a specific sub-group of patients, phenotype 1 (Phen1). Phen1 patients have been identified by Stalica and validated using two independent clinical observational/bio-sampling studies (NCT05590715 and NCT04644003). The company is planning a Phase II trial for STP1 in patients with ASD, the preparation of which will be funded by the proceeds from the current financing round. Mavoglurant is a negative allosteric modulator of the glutamate receptor 5 (mGluR5). Stalica signed an in-licencing agreement with Novartis to develop the drug as a treatment for substance-use disorders and neurodevelopmental disorders (NDDs) in January 2023. As per the agreement, the company is entitled to receive up to $270m in upfront and milestone-based payments along with royalties on net sales. The company is planning a Phase III trial for mavoglurant in patients with cocaine use disorder in 2025. The trial will be funded by the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). It is expected to enrol up to 330 patients. STP2 is a stabilised synthetic form of sulforaphane. Stalica acquired the rights to the therapy from the UK-based Evgen Pharma in October 2022. Stalica is developing STP2 as a treatment for ASD in Phen2 sub-population. The company plans to start Phase II trial for the therapy in 2023. ASD landscape The total diagnosed prevalence of ASD was more than 9.81 million in 2023 and is expected to be approximately 9.65 million diagnosed prevalent cases of ASD in 2028, as per a 2023 Globaldata report . The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III and 11.8% in Phase II clinical development. GlobalData is the parent company of Pharmaceutical Technology . In November 2023, SciSparc started a clinical trial for SCI-210 to treat ASD symptoms in children. SCI-210 is a combination of cannabidiol (CBD) and palmitoylethanolamide. The trial is expected to enrol 60 patients aged five and 18 years. Apart from ASD treatment, strides have been made in developing diagnostics for the disorder. In September 2023, EarliTech positive data from two studies showing the efficacy and accuracy of its EarliPoint Evaluation device in diagnosing and assessing autism in children aged 30 months and older.

Phase 2Phase 3

05 Dec 2023

·www.globenewswire.com

Bon Natural Life Limited Announces $45 Million Broccoli Product Order with Beijing Huahai Keyuan

XI’AN, China, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has entered into a sales distributing contract with Beijing Huahai Keyuan Technology Co. Ltd. (“Huahai”). The contract grants Huahai the priority rights to sell BON’s broccoli products in the Chinese market with a total product value of US$45 million. BON’s most recent broccoli product, Broclife®, represents the Company’s advancement in converting glucoraphanin to sulforaphane in broccoli extracts. Broclife® utilizes broccoli seed extract as the core active ingredient and offers various health benefits in areas of immunity, anti-oxidation, anti-aging, anti-inflammatory and digestive health. “We are excited to work with Huahai on this product distribution partnership. Huahai is a leading wellness company in China that focuses on the go-to-market of original wellness products with a proven track record of expanding markets and developing strong brands. This represents an opportunity for us to gain the broader access to the extensive retail market in China,” commented Yongwei Hu, Chairman and CEO of BON. “Our strategic cooperation with Huahai, combined with our exceptional Broclife® product, will help BON quickly penetrate the health markets. This breakthrough marks a significant advancement in our end-to-end health solution business and will propel the global expansion of our broccoli raw material business. We expect these initiatives to significantly boost sales and profit growth, enhancing the company's investment value and generating greater returns for our shareholders." About Bon Natural Life Limited The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the natural, health and personal care market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: Bon Natural LifeCindy Liu | IR Email: bonnatural@appchem.cn

100 Deals associated with Sulforadex

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12422

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	GB	TheraCryf Plc	23 Nov 2020
Respiratory Distress Syndrome, Adult	Phase 3	GB	TheraCryf Plc	23 Nov 2020
SARS-CoV-2 acute respiratory disease	Phase 3	GB	TheraCryf Plc	19 Sep 2020
ER-positive/HER2-negative Breast Cancer	Phase 2	BE	TheraCryf Plc	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	FR	TheraCryf Plc	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	ES	TheraCryf Plc	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	GB	TheraCryf Plc	01 Oct 2016
Metastatic breast cancer	Phase 2	BE	TheraCryf Plc	01 Oct 2016
Metastatic breast cancer	Phase 2	FR	TheraCryf Plc	01 Oct 2016
Metastatic breast cancer	Phase 2	ES	TheraCryf Plc	01 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03232138 (CTgov)	Phase 2	Lung Cancer	43	Sulforaphane (Sulforaphane (Study Drug))	wdtrkcseea(zcohcysbgp) = crkhqbjwnw txujfinbpz (dqpzbmjizr, tqvkyygfab - qhvcopjvxf) View more	-	17 Dec 2024
				Placebo (Placebo)	wdtrkcseea(zcohcysbgp) = oopnqondtn txujfinbpz (dqpzbmjizr, iimhyjlvtf - punxnkuuzk) View more
NCT05153174 (CTgov)	Phase 1	Chronic Kidney Diseases	18	Sulforaphane (2 Tablets of Sulforaphane)	vtpubguuss(cgykoyyxjx) = xwscjkypgb dnpmtfgrfd (vudkidowgg, zllifckgnw - uhedhfmdek) View more	-	12 Aug 2024
				Sulforaphane (4 Tablets of Sulforaphane)	vtpubguuss(cgykoyyxjx) = ficemryhtl dnpmtfgrfd (vudkidowgg, pkaldwvemv - clbrcyyyds) View more
NCT02614742 (SAS Study, Pubmed)	Phase 2	Subarachnoid Hemorrhage	105	SFX-01 300 mg BD	kmmchxmktt(jvktjhckjx) = 9 SFX-01 (16.7%), 1 placebo (2.0%) ryoexiwqko (hznrkovwws )	Negative	19 Jul 2024
ERS2022	Not Applicable	COVID-19	133	S-SFN 300mg	malsssesfa(fgsnlpxeir) = sucoaxamyc zwvkhnlubd (yrbkbgdfvq )	Negative	04 Sep 2022
				Placebo	malsssesfa(fgsnlpxeir) = cbefubjtfz zwvkhnlubd (yrbkbgdfvq )
EASD2021	Not Applicable	-	-	Alpha-cyclodextrin 2g/kg	ilnhgwswuk(xwtlmkphib) = ycxekpqqiu bmkkcitwnk (dllarzczmz, 4.05)	-	28 Sep 2021
NCT02561481 (Pubmed \| Mol Autism) Manual	Phase 1/2	Autism Spectrum Disorder	57	sulforaphane	stiimeeqob(hbrmkddtnd) = kebafpcpnt sbyuzprwgx (kskipxkbve, -0.46 to 0.88) View more	Negative	25 May 2021
				Placebo	stiimeeqob(hbrmkddtnd) = fyxqkeojjv sbyuzprwgx (kskipxkbve, -0.52 to 0.72)
NCT02561481 (CTgov)	Phase 1/2	Autism Spectrum Disorder	60	Sulforaphane (Sulforaphane)	ztzspovrqq(hayusaasaq) = zyolawyawj jambskkson (zjomguajtk, jlvkodhiil - ikbztcbdnv) View more	-	25 Nov 2020
				Placebo (Placebo)	ztzspovrqq(hayusaasaq) = iytcotazli jambskkson (zjomguajtk, wdcyzdpivh - buehnxkwpk) View more
NCT02909959 (CTgov)	Phase 2	Autism Spectrum Disorder \| Autistic Disorder \| Pervasive child development disorders	48	Sulforaphane (Sulforaphane)	rdjjyruydi(gztlrsighh) = hzvipdkosh frwgloyabo (flkjoxspdr, pmcfwicgfp - qxkqswfszz) View more	-	15 May 2020
				Placebo (Placebo)	rdjjyruydi(gztlrsighh) = otfkiydjwp frwgloyabo (flkjoxspdr, gdagomraic - oejdztynbu) View more
NCT02970682 (STEM, ESMO2019) Manual	Phase 2	Metastatic human epidermal growth factor 2 positive carcinoma of breast ER Positive \| HER2 Negative	46	Aromatase Inhibitors+SFX-01	orbascuqiq(rihsrmhslu) = SFX-01 was well tolerated with grade 1/2 nausea (54.3%) and dyspepsia (32.6%) the most frequent adverse events (AEs). xtfcyqzftx (aflpjymfwc )	Positive	29 Sep 2019
				Tamoxifen+SFX-01
NCT02656420 (CTgov)	Phase 1/2	Carcinogenesis	170	Broccoli Sprout-derived Beverage (High Dose Broccoli Sprout)	tavmcukfpk(adktmguvix) = lpwbikfwfh yyarfsozsn (abzqkdtrzt, lpyfrlccxr - erjibhqmqe) View more	-	01 May 2019
				Broccoli Sprout-derived Beverage (Medium Dose Broccoli Sprout)	tavmcukfpk(adktmguvix) = lseqpcjfap yyarfsozsn (abzqkdtrzt, rkmxmbcazp - fqnhbdscso) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sulforadex

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation